Sugi Predict

Sugi Predict / Compounds / SCHEMBL6358663

SCHEMBL6358663

SCHEMBL6358663

CCCCNC(=O)c1ccc(C#N)cc1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 2/20 0.62
▸ SIGMAR1 Q99720 2/20 0.59
▸ L3MBTL1 Q9Y468 1/20 0.58
▸ SMN1; SMN2 Q16637 1/20 0.57
▸ MEN1 O00255 1/20 0.56
▸ KMT2A Q03164 1/20 0.56
▸ EGLN2 Q96KS0 1/20 0.56
▸ NAAA Q02083 2/20 0.55
▸ NAMPT P43490 1/20 0.55
▸ TMEM97 Q5BJF2 1/20 0.54
▸ RAB9A P51151 2/20 0.54
▸ NPC1 O15118 1/20 0.54
▸ EPHX2 P34913 2/20 0.54
▸ MLYCD O95822 1/20 0.52
▸ HDAC3 O15379 1/20 0.52
▸ HDAC1 Q13547 1/20 0.52
▸ GFER P55789 1/20 0.52
▸ TSHR P16473 1/20 0.51
▸ HTT P42858 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22265515 0.94 L3MBTL1 (0.68) MGLLSIGMAR1L3MBTL1SMN1; SMN2MEN1
SCHEMBL28929238 0.94 L3MBTL1 (0.68) MGLLSIGMAR1L3MBTL1SMN1; SMN2MEN1
SCHEMBL6359493 0.90 KMT2A (0.59) MGLLSIGMAR1L3MBTL1MEN1KMT2A
SCHEMBL5536198 0.90 NAMPT (0.64) SIGMAR1MEN1KMT2ANAMPTTMEM97
SCHEMBL5543873 0.88 NAMPT (0.67) MGLLSIGMAR1L3MBTL1MEN1KMT2A
SCHEMBL5546309 0.88 NAMPT (0.67) MGLLSIGMAR1L3MBTL1MEN1KMT2A
SCHEMBL20707157 0.88 NAMPT (0.67) MGLLSIGMAR1L3MBTL1MEN1KMT2A
SCHEMBL5515823 0.88 NAMPT (0.67) MGLLSIGMAR1L3MBTL1MEN1KMT2A
SCHEMBL28326194 0.86 L3MBTL1 (0.73) L3MBTL1SMN1; SMN2MEN1KMT2ANAAA
SCHEMBL6948202 0.86 SIGMAR1 (0.57) SIGMAR1MEN1KMT2ANAMPTTMEM97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590083-B2 Inhibitors of spinster homolog 2 (SPNS2) for use in therapy UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2026-03-31 — — US disclosed
US-20230373937-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. 2023-11-23 — — US disclosed
US-20230373937-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. 2023-11-23 — — US disclosed
US-20230373937-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. 2023-11-23 — — US disclosed
EP-4210824-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY University of Virginia Patent Foundation (US) 2023-07-19 — — EP disclosed
US-20220177416-A1 PREPARING METHOD OF COMPOUNDS INCLUDING AMIDE GROUP FROM TERTIARY AMINE Research & Business Foundation Sungkyunkwan University (KR) 2022-06-09 — — US disclosed
US-20220089581-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2022-03-24 — — US disclosed
WO-2022056042-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2022-03-17 — — WO disclosed
EP-3914592-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY University of Virginia Patent Foundation (US) 2021-12-01 — — EP disclosed
WO-2020154431-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY LYNCH KEVIN R (US) 2020-07-30 — — WO disclosed
WO-2020154431-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY LYNCH KEVIN R (US) 2020-07-30 — — WO disclosed
US-8168654-B2 Quinuclidine derivatives binding to mucarinic M3 receptors NOVARTIS AG (CH) 2012-05-01 — — US disclosed
US-8168654-B2 Quinuclidine derivatives binding to mucarinic M3 receptors NOVARTIS AG (CH) 2012-05-01 — — US disclosed
US-20100041887-A1 QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS COLLINGWOOD STEPHEN PAUL 2010-02-18 — — US disclosed
US-20100041887-A1 QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS COLLINGWOOD STEPHEN PAUL 2010-02-18 — — US disclosed
US-20070060563-A1 Quinuclidine derivatives binding to mucarinic m3 receptors NOVARTIS AG (CH) 2007-03-15 — — US disclosed
US-20070060563-A1 Quinuclidine derivatives binding to mucarinic m3 receptors NOVARTIS AG (CH) 2007-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089581-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY SPNS2, SPCS2, SMN1; SMN2 MGLL 4803/4885SIGMAR1 1855/4885L3MBTL1 3898/4885
US-20070060563-A1 Quinuclidine derivatives binding to mucarinic m3 receptors CHRM3, CHRM2, CHRM1 MGLL 3268/4885SIGMAR1 151/4885L3MBTL1 3806/4885
US-20220177416-A1 PREPARING METHOD OF COMPOUNDS INCLUDING AMIDE GROUP FROM TERTIARY AMINE TYR, NAT1, SAT1 MGLL 3446/4885SIGMAR1 544/4885L3MBTL1 2836/4885
US-20100041887-A1 QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS CHRM3, CHRM2, CHRM1 MGLL 3268/4885SIGMAR1 151/4885L3MBTL1 3806/4885
US-20230373937-A1 INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY SPNS2, SPCS2, SMN1; SMN2 MGLL 4788/4885SIGMAR1 2041/4885L3MBTL1 3697/4885
US-12590083-B2 Inhibitors of spinster homolog 2 (SPNS2) for use in therapy SPNS2, SLC20A2, S1PR2 MGLL 1829/4885SIGMAR1 2272/4885L3MBTL1 4422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.